<DOC>
	<DOC>NCT01298700</DOC>
	<brief_summary>This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension or glaucoma in each eye Requires intraocular pressure (IOP)lowering therapy in both eyes Best corrected visual acuity of 20/100 or better in each eye Ocular seasonal allergies within 2 years Required chronic use of ocular medications during the study (intermittent use of artificial tears is allowed) Ocular surgery or laser within 3 months Anticipated wearing of contact lenses during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>